SALT LAKE CITY, Sept. 11, 2017 -- Predictive Technology Group, Inc. (OTCPINK:PRED) proceeds with the evaluation of moving the Company’s trading status to OTCQB on OTC MARKETS.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/43bf0c1d-b26b-4860-bc3f-88cac88bd952
Management determined the “NEW” Alternative Listing Standards which became available to issuers could be prudent, saving time and cost effective objective to uplift PRED’s tradable shares.
Effective May 18, 2017, the OTC Markets amended its rules for the OTCQB qualification which allows the issuers that follow “Alternative Reporting Standard.” The new standard for OTCQB for alternative reporters now allows a company to file 1-year audited financial reports. These reports are to US GAAP standards through a PCAOB qualified auditor. A company must still maintain a bid price of $0.01 per shares, needs a board of directors with at least two independent directors, and an audit committee comprised of a majority of independent directors.
OTC MARKETS believes these updated rules for OTCQB provides non-SEC Reporting companies with the benefits of public trading while lowering the cost and complexity of being public. The new market standards give “Alternative Reporting” companies an efficient way to raise their profile among the investor and broker dealer communities, access greater liquidity, and trade on a SEC-recognized market. Thus, removing the trading restrictions placed on “Pink” market securities.
Based on these news standards, PRED’s management remains confident that uplifting to the OTCQB can be done timely. Once management and the board at PRED finish their due diligence on OTC MARKETS’ “ALTERNATIVE REPORTING STANDARDS,” expect more news to follow.
Management continues on its fiduciary path with a primary objective of creating shareholder value.
About Predictive Technology Group, Inc.:
Predictive Technology Group, Inc. (OTCPINK:PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases' onsets and progressions. PRED's subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person's risk of disease and therapeutic products effectively designed to prevent and treat diseases.
For further information about PRED and this release contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and [email protected], www.predictivetechnologygroup.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.
Contact
Rich Kaiser
YES INTERNATIONAL
757-306-6090
www.predictivetechnologygroup.com


Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Apple Turns 50: From Garage Startup to AI Crossroads
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 



